There were 349 press releases posted in the last 24 hours and 440,428 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image